Skip to main content

Advertisement

SpringerLink
Log in

Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

In multinodular goitre (MNG), low radioiodine (RAI) activity after recombinant human (rh) TSH is able to reduce thyroid volume (TV) and improve symptoms. Our aim was to evaluate the long-term outcome of RAI after rhTSH treatment in patients who were divided according to their baseline TSH levels. Eighteen patients (69.2 ± 6.1 year) presented non-toxic (TSH >0.3 mIU/l) MNG (TV: 61.0 ± 3.8 ml; group 1), while 13 patients (74.1 ± 7.9 year) had non-autoimmune pre-toxic (TSH <0.3 mIU/l) MNG (TV: 82.6 ± 14.4 ml; group 2). TSH, thyroid hormones, TV (by ultrasonography), body mass index (BMI), symptoms and quality of life (QoL) were evaluated. Treatment induced short-term thyrotoxicosis in both groups, but this was slightly more marked in group 2 than in group 1. The number and severity of adverse events were similar. The follow-up period was 55.3 ± 4.1 months in group 1 and 57.2 ± 5.1 months in group 2. The final TV reduction was similar in groups 1 (63.4 ± 3.6 %) and 2 (57.2 ± 4.6 %) and TV reduction positively correlated only with initial TV. At the last examination, 14 group-1 subjects were on L-T4 therapy, while 2 group-2 subjects were on methimazole. An increase in BMI was noted only in group 2. MNG-related symptoms were significantly reduced in both groups. Symptoms related to sub-clinical hyperthyroidism improved in group 2, while no significant changes in QoL were noted in either group. This study confirms the effectiveness of rhTSH adjuvant treatment in reducing TV after low RAI activities, irrespective of baseline thyroid status. TSH levels <0.3 mIU/l proved to be predictive of a more severe thyrotoxic phase after rhTSH and RAI, while initial TSH levels >0.3 mIU/l were more frequently followed by a need for L-T4 therapy. Compressive symptoms improved in the majority of subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. L. Hegedus, S.J. Bonnema, F.N. Bennedback, Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. 24, 102–132 (2003). doi:10.1210/er.2002-0016

    Article  PubMed  Google Scholar 

  2. S.J. Bonnema, L. Hegedus, A 30-year perspective on radioiodine therapy of benignant non-toxic multinodular goiter. Curr. Opin. Endocrinol. Diabetes Obes. 16, 379–384 (2009). doi:10.1097/MED.0b013e32832ff2e1

    Article  CAS  PubMed  Google Scholar 

  3. R.H. Grogan, E.J. Mitmaker, J. Hwang, J.E. Gosnell, Q.-Y. Duh, O.H. Clark, W.T. Shen, A population-based prospective cohort study of complication after thyroidectomy in the elderly. J. Clin. Endocrinol. Metab. 97, 1645–1653 (2012). doi:10.1210/jc.2011-1162

    Article  CAS  PubMed  Google Scholar 

  4. S.J. Bonnema, H. Bertelsen, J. Mortensen, P.B. Andersen, D.U. Knudsen, L. Bastholt, L. Hegedus, The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect of thyroid function and size and pulmonary function. J. Clin. Endocrinol. Metab. 84, 3638–3641 (1999). doi:10.1210/jc.84.10.3636

    Google Scholar 

  5. D. Huysmans, A. Hermus, M. Edelbroek, J. Barentsz, F. Corstens, P. Kloppenborg, Radioiodine for non-toxic multinodular goiter. Thyroid 7, 235–239 (1997)

    Article  CAS  PubMed  Google Scholar 

  6. B. Nygaard, L. Hegedus, M. Gervil, H. Hjalgrim, P. Soe-Jensen, J.M. Hansen, Radioiodine treatment of multinodular non-toxic goitre. BMJ 307, 828–832 (1993). doi:10.1136/bmj.307.6908.828

    Article  CAS  PubMed  Google Scholar 

  7. D.A. Huysmans, W.A. Nieuwlaat, R.J. Erdtsieck, A.P. Schellekens, J.W. Bus, B. Bravenboer, A.R. Hermus, Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxix nodular goiter. J. Clin. Endocrinol. Metab. 85, 3592–3596 (2000). doi:10.1210/jc.85.10.3592

    CAS  PubMed  Google Scholar 

  8. W.A. Nieuwlaat, A.R. Hermus, F. Sicro-Prndelj, F.H. Corstens, D.A. Huysmans, Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J. Clin. Endocrinol. Metab. 86, 5330–5336 (2001). doi:10.1210/jc.86.11.5330

    Article  CAS  PubMed  Google Scholar 

  9. W.A. Nieuwlaat, D.A. Huysmans, H.C. Van den Bosch, G.C. Sweep, H.A. Ross, F.H. Corstens, A.R. Hermus, Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J. Clin. Endocrinol. Metab. 88, 3121–3129 (2003). doi:10.1210/jc.2002-021554

    Article  CAS  PubMed  Google Scholar 

  10. C.C. Albino, C.O. Mesa Jr, M. Olandoski, C.E. Ueda, L.C. Woellner, C.A. Goedert, A.M. Souza, H. Graf, Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J. Clin. Endocrinol. Metab. 90, 2775–2780 (2005). doi:10.1210/jc.2004-0458

    Article  CAS  PubMed  Google Scholar 

  11. C.C. Albino, H. Graf, G. Paz-Filho, L.A. Diehl, M. Olandoski, A. Sabbag, C. Buchpiguel, Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter. Braz. J. Med. Biol. Res. 43, 303–309 (2010)

    Article  CAS  PubMed  Google Scholar 

  12. S.J. Bonnema, V.E. Nielsen, H. Boel-Jorgensen, P. Gruppe, P.B. Anderson, L. Bastholt, L. Hegedus, Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotorpin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomised trail. J. Clin. Endocrinol. Metab. 92, 3424–3428 (2007). doi:10.1210/jc.2007-0501

    Article  CAS  PubMed  Google Scholar 

  13. O. Cohen, J. Ilany, C. Hoffman, D. Olchovsky, S. Dabhi, A. Karasik, E. Goshen, G. Rotenberg, S.T. Zwas, Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur. J. Endocrinol. 154, 243–252 (2006). doi:10.1530/eje.1.02094

    Article  CAS  PubMed  Google Scholar 

  14. E.R. Cubas, G.J. Paz-Filho, M. Olandoski, C.A. Goedert, L.C. Woellner, G.A. Carvalho, H. Graf, Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int. J. Clin. Pract. 63, 583–590 (2009). doi:10.1111/j.1742-1241.2008.01904.x

    Article  CAS  PubMed  Google Scholar 

  15. S. Fast, L. Hegedus, P. Grupe, V.E. Nielsen, C. Bluhme, L. Bastholt, S.J. Bonnema, Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J. Clin. Endocrinol. Metab. 95, 3719–3725 (2010). doi:10.1210/jc.2010-0634

    Article  CAS  PubMed  Google Scholar 

  16. M. Giusti, C. Cappi, B. Santaniello, E. Ceresola, C. Augeri, C. Lagasio, F. Minuto, Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large multinodular goiter. Minerva Endocrinol. 31, 191–209 (2006)

    CAS  PubMed  Google Scholar 

  17. M. Giusti, M. Caputo, I. Calamia, M.C. Bagnara, E. Ceresola, M. Schiavo, M. Mussap, D. Ferone, F. Minuto, M. Bagnasco, Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. Thyroid Res. 2, 6 (2009). doi:10.1186/1756-6614-2-6

    Article  PubMed Central  PubMed  Google Scholar 

  18. V.E. Nielsen, S.J. Bonnema, H. Boel-Jorgensen, P. Gruppe, L. Hegedus, Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic goiter: a prospective randomised double-blind trial. Arch. Intern. Med. 166, 1476–1482 (2006). doi:10.1001/archint.166.14.1476

    Article  CAS  PubMed  Google Scholar 

  19. G.J. Paz-Filho, C.O. Mesa-Junior, M. Olandoski, L.C. Woellner, C.A. Goedert, C.L. Boguszewski, G.A. Carvalho, H. Graf, Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz. J. Med. Biol. Res. 40, 1661–1670 (2007)

    Article  CAS  PubMed  Google Scholar 

  20. R. Romao, I.G.S. Rubio, E.K. Tominori, Y. Camargo, M. Knobel, G. Medeiros-Neto, High prevalence of side effect after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid 19, 945–951 (2009)

    Article  CAS  PubMed  Google Scholar 

  21. M.N. Silva, I.G.S. Rubio, R. Romao, E.M.M.S. Gebrin, C. Buchpiguel, E. Tomimori, R. Camargo, M.S. Cardia, G. Medeiros-Neto, Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goiter. Clin. Endocrinol. (Oxf) 60, 300–308 (2004). doi:10.1046/j.1365-2265.2003.01918.x

    Article  CAS  Google Scholar 

  22. S. Fast, V.E. Nielsen, P. Groupe, B. Boel-Jorgensen, L. Bastholt, P.B. Andersen, S.J. Bonnema, L. Hegedus, Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J. Clin. Endocrinol. Metab. 97, 2653–2660 (2012). doi:10.1210/jc.2011-3335

    Article  CAS  PubMed  Google Scholar 

  23. M.S. Cardia, I.G. Rubio, G. Medeiros-Neto, Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin. Endocrinol. (Oxf) 64, 474 (2006). doi:10.1111/j.1365-2265.2005.02419.x

    Google Scholar 

  24. G.J. Paz-Filho, C.O. Mesa, G.A. Carvalho, C.A. Goedert, H. Graf, Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years. Clin. Endocrinol. (Oxf) 69, 345–346 (2008). doi:10.1111/j.1365-2265.2007.03165.x

    Article  CAS  Google Scholar 

  25. A.C. Traino, F. Di Martino, M. Lazzeri, M.G. Stabia, Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves’ hyperthyroidism. Phys. Med. Biol. 45, 121–129 (2000). doi:10.1088/0031-9155/45/1/309

    Article  CAS  PubMed  Google Scholar 

  26. W.Z. Billewicz, R.S. Chapman, J. Crooks, M.E. Day, J. Gossage, E. Wayne, J.A. Young, Statistical methods applied to the diagnosis of hypothyroidism. Q. J. Med. 150, 255–266 (1969)

    Google Scholar 

  27. M. Giusti, G. Melle, M. Fenocchio, L. Mortara, F. Cecoli, V. Caorsi, D. Ferone, F. Minuto, E. Rasore, Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. J. Zehjiang Univ. Sci. B. 12, 163–173 (2011). doi:10.1631/jzus.B.1000382

    Article  Google Scholar 

  28. V.E. Nielsen, S.J. Bonnema, L. Hegedus, Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J. Clin. Endocrinol. Metab. 91, 1317–1322 (2006). doi:10.1210/jc.2005-2137

    Article  CAS  PubMed  Google Scholar 

  29. H. Graf, S. Fast, F. Pacini, A. Pinchera, A. Leung, M. Vaisman, C. Reiners, J.L. Wemeau, D. Huysmans, W. Harper, A. Driedger, H. de Noemberg Souza, M.G. Castagna, L. Antonangeli, L. Braverman, R. Corbo, C. Duren, E. Proust-Lemoine, A. Edelbroek, C. Mariott, I. Rachinsky, P. Gruppe, T. Watt, J. Magner, L. Hegedus, Modified-Release Recombinant Human TSH (MRrhTSH) augments the effect of ¹³¹I therapy in benign multinodular goiter; results from a multicenter international, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 1368–1376 (2011). doi:10.1210/jc.2010-1193

    Article  CAS  PubMed  Google Scholar 

  30. R. Crevenna, G. Zetting, M. Keilani, M. Posch, M. Schmidinger, C. Pirich, M. Nuhr, M. Wolzt, M. Quittan, V. Fialka-Moser, Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support Care Center 11(9), 597–603 (2003). doi:10.1007/s00520-003-0474-4

    Article  Google Scholar 

  31. J. Lee, M.J. Yun, K.H. Nam, W.Y. Choung, E.Y. Soh, C.S. Park, Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20, 173–179 (2010)

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have nothing to declare.

Author information

Authors and Affiliations

  1. Endocrine Unit, San Martino University Hospital, Genoa, Italy

    M. Giusti, V. Caorsi, L. Mortara, E. Monti & F. Minuto

  2. Radiometabolic Therapy Unit, San Martino University Hospital, Genoa, Italy

    M. Caputo, M. Schiavo & M. Bagnasco

  3. Medical Physics Unit, San Martino University Hospital, Genoa, Italy

    M. C. Bagnara

  4. UO Clinica Endocrinologica, Azienda Ospedaliera Universitaria San Martino, Viale Benedetto XV, 6, 16100, Genoa, GE, Italy

    M. Giusti

Authors
  1. M. Giusti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Caorsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Mortara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Caputo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Monti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Schiavo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. C. Bagnara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Minuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Bagnasco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Giusti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giusti, M., Caorsi, V., Mortara, L. et al. Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre. Endocrine 45, 221–229 (2014). https://doi.org/10.1007/s12020-013-9959-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-9959-1

Keywords

Search

Navigation